Skip to main content
Premium Trial:

Request an Annual Quote

CORRECTED: Affymetrix Reports Q1 Revenue Rise

This article has been corrected from a previous version that misstated the company's cash holdings.


SAN FRANCISCO, April 24 - Affymetrix on Wednesday posted increased revenues for the first quarter 2002.


For the three months ended March 31, the company reported revenues of $68.1 million, compared with $54.9 million in the same period one year ago. The first quarter revenue includes $6 million from wafers sold at cost to subsidiary Perlegen Sciences, according to Affymetrix.


Affymetrix said that it had a pro forma profit of $400,000, or $.01 a share, for the first quarter of 2002, its second consecutive quarter of pro forma profit.


Under standard rules, Affymetrix reported a $3.6 million loss, or $.06 a share, compared to a loss of $10.8 million, or $.19 per share, for the year-ago period.


The company said that revenue from its GeneChip arrays grew 38 percent to $57.2 million for the first quarter of 2002 compared to the same period a year ago.


Research and development dropped to $16.7 million for the first quarter versus $19.3 million for the year-ago period, though the company said that the 2001 numbers included Perlegen-associated R&D.


Affymetrix said it has $65 million in cash and cash equivalents and $286 million in available-for-sale securities.


The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.